Asset Details
Do you wish to reserve the book?
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?
Do you wish to request the book?
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?
2021
Overview
Preclinical studies on mice fed with high-fat diet (HFD) have shown that the adipocytes and adipose tissue-associated macrophages release a plethora of inflammatory mediators, including interleukin (IL)-1, IL-6, tumor necrosis factor (TNF) and monocyte chemoattractant protein-1, leading to a condition of systemic inflammation and oxidative stress (Ellulu et al., 2017). At present, the available pharmacological tools to manage obesity are unsatisfactory in terms of efficacy, safety and long-term maintenance of weight loss. [...]the identification of novel molecular targets, aimed at developing innovative anti-obesity treatments, represents a challenging and exciting field of high scientific interest. In the same study, the authors also showed that the systemic administration of CGS21680, beyond to reduce the body weight gain, induced the browning of WAT and improved glucose tolerance in HFD mice (Gnad et al., 2014). Other authors observed an anti-hypertensive effect after treatment with the A2AR agonist CGS21680 in a mouse model of hypertension induced by partial constriction of the renal artery, highlighting a modulatory role of A2ARs in regulating vascular smooth muscle relaxation/contraction (Schindler et al., 2005).
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
